Royalty Pharma Correlations

RPRX Stock

USD 26.43 0.03 0.11%

The current 90-days correlation between Royalty Pharma Plc and Ascendis Pharma AS is 0.22 (i.e., Modest diversification). The correlation of Royalty Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.

Royalty Pharma Correlation With Market

Significant diversification

The correlation between Royalty Pharma Plc and DJI is 0.04 (i.e., Significant diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Royalty Pharma Plc and DJI in the same portfolio, assuming nothing else is changed.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Royalty Pharma Plc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Moving together with Royalty Stock

0.63	A	Agilent Technologies Earnings Call Today	Pair Corr
0.75	ME	23Andme Holding	Pair Corr
0.78	VALN	Valneva SE ADR	Pair Corr
0.85	JNJ	Johnson Johnson Fiscal Year End 28th of January 2025	Pair Corr
0.81	LLY	Eli Lilly Sell-off Trend	Pair Corr
0.88	MRK	Merck Company Fiscal Year End 6th of February 2025	Pair Corr
0.71	PFE	Pfizer Inc Aggressive Push	Pair Corr
0.8	GMAB	Genmab AS	Pair Corr
0.8	INZY	Inozyme Pharma	Pair Corr
0.72	IPSC	Century Therapeutics	Pair Corr
0.84	LEGN	Legend Biotech Corp	Pair Corr
0.62	LYRA	Lyra Therapeutics	Pair Corr
0.75	MTEM	Molecular Templates	Pair Corr
0.8	NKTX	Nkarta Inc	Pair Corr

Moving against Royalty Stock

0.82	GILD	Gilead Sciences	Pair Corr
0.79	BMY	Bristol Myers Squibb Sell-off Trend	Pair Corr
0.68	EWTX	Edgewise Therapeutics	Pair Corr
0.47	VRDN	Viridian Therapeutics	Pair Corr
0.4	KZR	Kezar Life Sciences	Pair Corr
0.35	KTTAW	Pasithea Therapeutics	Pair Corr
0.84	RVMD	Revolution Medicines	Pair Corr
0.82	AMLX	Amylyx Pharmaceuticals	Pair Corr
0.79	MNPR	Monopar Therapeutics	Pair Corr
0.64	AKRO	Akero Therapeutics	Pair Corr
0.6	MDGL	Madrigal Pharmaceuticals	Pair Corr
0.45	RNXT	RenovoRx	Pair Corr

Related Correlations Analysis

	PRME	RPHM	DNA	OCEA	ADPT	VECT	KNTE	IKNA	ASND	APLS
PRME		-0.45	0.38	0.47	0.19	-0.09	-0.36	0.33	-0.05	0.31	PRME
RPHM	-0.45		-0.34	-0.38	-0.11	0.22	-0.13	-0.12	-0.31	-0.05	RPHM
DNA	0.38	-0.34		0.02	0.49	0.37	0.35	0.28	0.37	-0.52	DNA
OCEA	0.47	-0.38	0.02		-0.41	-0.59	-0.03	-0.1	0.25	0.52	OCEA
ADPT	0.19	-0.11	0.49	-0.41		0.44	0.1	0.32	0.01	-0.44	ADPT
VECT	-0.09	0.22	0.37	-0.59	0.44		0.01	0.1	-0.43	-0.82	VECT
KNTE	-0.36	-0.13	0.35	-0.03	0.1	0.01		-0.15	0.55	-0.4	KNTE
IKNA	0.33	-0.12	0.28	-0.1	0.32	0.1	-0.15		0.06	0.03	IKNA
ASND	-0.05	-0.31	0.37	0.25	0.01	-0.43	0.55	0.06		0.03	ASND
APLS	0.31	-0.05	-0.52	0.52	-0.44	-0.82	-0.4	0.03	0.03		APLS
	PRME	RPHM	DNA	OCEA	ADPT	VECT	KNTE	IKNA	ASND	APLS

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

Correlation Matchups

Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.

High positive correlations

ASND	+ 0.55	KNTE
APLS	+ 0.52	OCEA
ADPT	+ 0.49	DNA
OCEA	+ 0.47	PRME
VECT	+ 0.44	ADPT
DNA	+ 0.38	PRME

High negative correlations

APLS	- 0.82	VECT
VECT	- 0.59	OCEA
APLS	- 0.52	DNA
RPHM	- 0.45	PRME
APLS	- 0.44	ADPT
ASND	- 0.43	VECT

Risk-Adjusted Indicators

There is a big difference between Royalty Stock performing well and Royalty Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Royalty Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
PRME	3.94	(0.51)	0.00	(0.13)	0.00	0.00	7.74	(9.09)	25.80
RPHM	2.38	0.31	0.06	2.44	2.63	(3.25)	6.12	(4.88)	15.91
DNA	4.12	(0.39)	0.00	(0.03)	0.00	0.00	8.95	(9.23)	27.15
OCEA	3.56	(0.56)	0.00	(1.39)	0.00	0.00	7.46	(6.93)	28.33
ADPT	3.69	(0.15)	0.02	0.07	3.69	(4.74)	9.71	(7.87)	31.46
VECT	2.63	1.07	0.54	3.09	0.88	(3.64)	5.61	(3.08)	39.30
KNTE	4.52	0.16	0.00	0.02	0.00	0.00	8.70	(9.14)	22.40
IKNA	1.09	(0.07)	(0.07)	(0.01)	1.39	(1.50)	1.81	(1.74)	13.50
ASND	2.04	(0.17)	0.00	(0.08)	0.00	0.00	4.75	(3.56)	22.16
APLS	2.39	(0.40)	0.00	(0.45)	0.00	0.00	4.31	(5.17)	15.97

Royalty Pharma Corporate Management

Eric Schneider	Senior Officer	Profile
George Lloyd	Executive Officer	Profile
Marshall MD	Executive Investments	Profile
Sandy Balkin	Senior Analytics	Profile
Sara Klymkowsky	Senior Investments	Profile
Ashwin MD	Executive Investments	Profile

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC